title: Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature.
authors.affiliation: Policy Analysis Inc. (PAI), Brookline, MA, USA. Electronic address: tdelea@pai2.com.
authors.forename: T E
authors.initials: TE
authors.lastname: Delea
authors.affiliation: University of Sheffield, School of Health and Related Research, Sheffield, UK.
authors.forename: J
authors.initials: J
authors.lastname: Karnon
authors.affiliation: Massachusetts General Hospital, Division of Hematology-Oncology, Boston, MA, USA.
authors.forename: P E
authors.initials: PE
authors.lastname: Goss
mesh_terms: D047072:Aromatase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D017698:Postmenopause
chemical_list: D047072:Aromatase Inhibitors